Histologix provides 100% QC of histology services for GLP and non-GLP compliant studies in a range of species from early stage discovery through regulatory preclinical toxicology to clinical trials.
Histologix provide specialist IHC and ISH services as well as histopathology, on behalf of its clients in many areas of research, including target validation and distribution in many therapeutic areas, oncology for example.
Using the GCP Accreditation and HTA licences, Histologix has expanded its services to include clinical trials and has performed analysis in Ph0, Ph1 and Ph2 trials.
Therapeutic molecular classes must undergo regulatory screening in human tissue as part of any preclinical safety assessment in line with US FDA, EU and Japanese MAFF regulations. Histologix has over 60 years of combined experience.
Digital Image Analysis is performed by an in-house specialist using the HALO image analysis software. Quantitative endpoints from IHC analyses adds an exponential level of value to your studies.
Subjective evaluation of stained tissues by veterinary and medical pathologists is a central part of the services offered by Histologix and compliments the quantitative studies. This is important in both preclinical animal safety studies as well as clinical trials.
Offering a range of validated immune biomarker assays which can be used to assess immune infiltrates and tumour microenvironment. A combination of immuno-oncology biomarkers with digital image analysis helps in predicting efficacy of immuno-therapeutics.
Histologix provides the Pharmaceutical and Biotechnology industry with specialist pathology services to assist drug development programmes ranging from Discovery, regulatory preclinical safety testing through to clinical trials and include human tissue sourcing, histology, medical and veterinary histopathology, immunohistochemistry, digital pathology and image analysis. These are technologies that have been developed with to meet current and future requirements of targeted therapy.
Through inward investment the services provided by Histologix Ltd use a range of highly sophisticated technologies and platforms aimed at standardising the various processes involved in order to achieve data generation that is consistent, accurate and reproducible and will assist our clients in the development of their drug programmes.
Histologix is a privately owned contract research organisation that provides specialist pathology services for the Pharmaceutical and Biotechnology industry. Set up in 2005 by industry specialists, Histologix is a GLP/GCP accredited, HTA-licenced company with an extensive and impressive track record of successfully delivering a range of IHC/ISH assays to large and small Pharma/Biotechnology companies and is a preferred supplier of these services to a number of companies.
Find out which conference Histologix is exhibiting at, updated news issues and current vacancies.